Physician profile
David Roth
NPI 1831197250
$1,730.29
in general payments reported to CMS, 2019-2025
15 companies · $407 in 2025
The $407 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.39 · 2020: $93.47 · 2021: $25.39 · 2022: $209 · 2023: $228 · 2024: $721 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,143 · Consulting Fee: $200 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,143.30 |
| Consulting Fee | $200.00 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $487.84 | 2022-2024 | Vraylar |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Axsome Therapeutics, INC. | $181.69 | 2024-2025 | Auvelity |
| Lundbeck LLC | $163.68 | 2019-2024 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $153.07 | 2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $137.55 | 2022-2024 | Rexulti |
| Almatica Pharma LLC | $102.80 | 2023-2024 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $85.64 | 2024-2025 | Spravato |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $56.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $53.34 | 2019-2021 | |
| Biogen, INC. | $27.80 | 2025 | Zurzuvae |
| Sunovion Pharmaceuticals INC. | $24.16 | 2022 | |
| Tempus Ai, INC | $23.72 | 2024 | |
| Neurocrine Biosciences, INC. | $18.70 | 2024 | Ingrezza |
| Supernus Pharmaceuticals, INC. | $14.05 | 2024 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.